Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.8%

2 terminated/withdrawn out of 17 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

24%

4 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

N/A

11(73.3%)

Phase 3

3(20.0%)

Phase 4

1(6.7%)

15Total

N/A(11)

Phase 3(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT07276282Phase 3Recruiting

Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction

Role: collaborator

NCT04854070Not ApplicableActive Not Recruiting

Intravascular Ultrasound Guidance for Complex High-risk Indicated Procedures

Role: collaborator

NCT04111770Not ApplicableCompleted

The OPTIMAL Randomized Controlled Trial

Role: collaborator

NCT03508219Not ApplicableTerminated

POLish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)

Role: collaborator

NCT06625801Not Yet Recruiting

IVUS CHIP UPP Registry

Role: collaborator

NCT02661451Not ApplicableActive Not Recruiting

Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Role: collaborator

NCT02695277Not ApplicableCompleted

Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation

Role: collaborator

NCT03023020Not ApplicableCompleted

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen

Role: collaborator

NCT02972671Not ApplicableUnknown

Trial of MiStent Compared to Xience in Japan

Role: collaborator

NCT02833948Phase 3Completed

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

Role: collaborator

NCT03196596Completed

Added Value of Patient-specific Computer Simulation in Transcatheter Aortic Valve Implantation (TAVI)

Role: collaborator

NCT03469856Not ApplicableUnknown

Acetyl Salicylic Elimination Trial: The ASET Pilot Study

Role: collaborator

NCT02176265Not ApplicableCompleted

Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation

Role: collaborator

NCT02303717Not ApplicableUnknown

Xience Versus Synergy in Left Main PCI